Public Company Healthcare

Merck KGaA

Darmstadt, Germany

Merck KGaA is a global science and technology company headquartered in Germany. It operates in Life Science (including MilliporeSigma), Healthcare, and Electronics, providing science and technology solutions that support customers across research, development, and production workflows.

Focus Areas
Biopharmaceutical purification (Protein A chromatography), Monoclonal antibody manufacturing solutions, Chromatography resins and application support

Tracked deals

3

3 tracked deals across 2025-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Merck KGaA Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Merck KGaA. 1 2025 ~2 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Merck KGaA to Acquire Silence Therapeutics for Approximately $1.3 Billion
    October 19, 2026
    Buyer
    Merck KGaA
    Target
    Silence Therapeutics
    Industry
    Biotechnology
    Location
    England, United Kingdom
    Type
    Buyout

    Merck KGaA entered into a definitive agreement to acquire all outstanding shares of Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion on an equity basis. The deal is expected to close in the first quarter of 2027, subject to shareholder, court, regulatory and other customary approvals; it would add Silence’s siRNA pipeline and development capabilities to Merck’s portfolio.

  • Merck KGaA to Acquire Bio-Techne for $11.3 Billion
    June 25, 2026
    Buyer
    Merck KGaA
    Target
    Bio-Techne Corporation
    Industry
    Healthcare Services
    Location
    Minnesota, United States
    Type
    Buyout

    Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

  • Merck KGaA Acquires JSR Life Sciences Chromatography Business
    October 19, 2025
    Buyer
    Merck KGaA
    Target
    JSR Life Sciences' Chromatography Business
    Industry
    Data & Analytics
    Location
    Belgium
    Type
    Buyout

    Merck KGaA entered into a definitive agreement and later completed the acquisition of the chromatography business of JSR Life Sciences. The deal adds Amsphere Protein A resins and Protein A chromatography capabilities to Merck’s downstream Process Solutions portfolio, strengthening scalable purification for monoclonal antibodies.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 1 tracked deal by Merck KGaA. Data & Analytics Buyers & Acquisitions 1 tracked deal by Merck KGaA. Healthcare Services Buyers & Acquisitions 1 tracked deal by Merck KGaA. Acquisitions in Minnesota 1 tracked deal by Merck KGaA.

Related articles

Selling a company? Get in front of buyers like Merck KGaA

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →